Cagrilintide is a compound under active clinical investigation, and it does not carry any approved drug label. Anyone researching this peptide should understand that its status is experimental rather than established.
Regulatory status
Cagrilintide is classified as unapproved research material. No regulatory agency has issued a label, and no approved brand names, indications, or dosing guidance exist for it. It is registered under the PubChem identifier 171397054, with a molecular formula of C194H312N54O59S2 and a molecular weight of approximately 4,409.
What cagrilintide is
Cagrilintide is a large peptide compound, built from a long chain of amino acids with a defined molecular structure. Because no approved label exists, there is no official description of a mechanism of action or intended use available for this compound.
Trial footprint
A total of 44 trials involving cagrilintide are registered. Several of these studies pair the compound with another agent under the name CagriSema. One Phase 3 study is examining effects on blood sugar and body weight in children and adolescents with type 2 diabetes, and is not yet recruiting. A Phase 2 study is investigating effects in people with type 2 diabetes and painful diabetic peripheral neuropathy, and is listed as active but not recruiting. A separate Phase 1 study, referenced under the code NNC0174-1213, is recruiting participants with overweight or obesity.